.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,855,906

« Back to Dashboard
Patent 5,855,906 protects FEMRING and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 5,855,906

Title: Intravaginal drug delivery devices for the administration of 17.beta.-oestradiol precursors
Abstract:The invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17.beta.-oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17.beta.-oestradiol precursor is a 17.beta.-oestradiol moiety in which the, or each, hydroxyl group of the 17.beta.-oestradiol moiety is blocked by a blocking group, which blocking group is readily removed from the 17.beta.-oestradiol in vivo. The 17.beta.-oestradiol precursor must have either a solubility in liquid silicone of not less than 0.1 mg/100 ml or a standard k value of not less than 0.1 .mu.g/day/mm. The 17.beta.-oestradiol precursor must also have a solubility in distilled water of not less than 1 .mu.g/100 ml.
Inventor(s): McClay; Allen (Cookstown, IE)
Assignee: Galen (Chemicals) Limited (Dublin, IE)
Application Number:08/849,329
Patent Claim Types:
see list of patent claims
Compound; Delivery; Device; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 2nd percentile
Forward Citations: 5th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apil
FEMRING
estradiol acetate
INSERT, EXTENDED RELEASE;VAGINAL021367-001Mar 20, 2003RXNo5,855,906► subscribe METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
Apil
FEMRING
estradiol acetate
INSERT, EXTENDED RELEASE;VAGINAL021367-002Mar 20, 2003RXYes5,855,906► subscribe METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,855,906

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
IrelandS940976Dec 19, 1994
IrelandS950247Apr 05, 1995
PCT Information
PCT FiledDecember 19, 1995PCT Application Number:PCT/IE95/00063
PCT Publication Date:June 27, 1996PCT Publication Number: WO96/19196

International Patent Family for Patent: 5,855,906

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina002010► subscribe
Austria178204► subscribe
Australia4399196► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc